Opinion|Videos|February 12, 2025
Other Emerging Intravesical Therapies in NMIBC
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how both TAR-200 and UGN-102/103 represent innovative approaches to intravesical drug delivery for bladder conditions. TAR-200 uses a novel silicone-based system designed for controlled gemcitabine release, potentially offering extended drug exposure compared with conventional instillations. UGN-102 and UGN-103 employ a proprietary RTGel technology that transforms from liquid to gel form at body temperature, allowing for longer retention of mitomycin (UGN-102) and high-dose botulinum toxin (UGN-103), respectively, in the bladder.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are your thoughts on novel continual intravesical release technologies that are currently in clinical trials?
- TAR-200 (SunRISe trials)
- UGN-102 (ENVISION) and UGN-103 (UTOPIA)
Advertisement
Related to this article
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
Advertisement
Advertisement
Trending on Urology Times
1
Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC
2
Sandip Prasad, MD, on the safety profile of mitomycin intravesical solution
3
Three-year data show durable responses with mitomycin intravesical solution
4
Urocross Expander System enters US commercial use for symptomatic BPH
5